TrialPhase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
Trial details
- Registry ID
- NCT05973006
- Phase
- Phase 3
Drug research
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as NVX-CoV2601
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNCT05973006 | Novavax | Phase 3 | Completed | 2024-04-01Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |